Clinical Trials

35 enrolled

Ovarian Neoplasms

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

210 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

157 enrolled 17 charts

Advanced Primary Liver Cancer

NCT05235100 2025-12-11

SPARE-02

30 enrolled

Sarcoma

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

885 enrolled

Stomach Neoplasms

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

81 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

64 enrolled 11 charts

Colonic Neoplasms

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Advanced Gastric Cancer

NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

93 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

25 enrolled

Stomach Neoplasms

NCT03417895 2024-08-07

PASSION

59 enrolled 17 charts

Thoracic

Small Cell Lung Carcinoma

NCT06376773 2024-04-19

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Completed

234 enrolled

Advanced Gastric Cancer

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

543 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

28 enrolled

Biliary Tract Neoplasms

NCT02329860 2024-01-22

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

400 enrolled 13 charts

Carcinoma, Hepatocellular

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

67 enrolled 12 charts

Stomach Neoplasms

NCT04393506 2023-11-22

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

21 enrolled

Mouth Neoplasms

NCT03267121 2023-10-17

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03180476 2023-04-14

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

21 enrolled

Nasopharyngeal Neoplasms

NCT03816553 2023-04-11

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

45 enrolled

Uterine Cervical Neoplasms

NCT03396211 2023-04-07

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

30 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01192971 2023-03-03

HCC

121 enrolled

Tumor-Agnostic

Neoplasms

NCT02976896 2023-02-16

Poetry-1

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT03365765 2023-02-14

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

63 enrolled

Apatinib

NCT05025033 2023-01-18

Chemotherapy Combined With Apatinib and PD-1 Antibody

30 enrolled

Stomach Neoplasms

NCT04350190 2023-01-13

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

25 enrolled

Nasopharyngeal Carcinoma

NCT04322552 2022-11-07

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

18 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04457180 2022-10-26

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

18 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

32 enrolled

Triple Negative Breast Neoplasms

NCT04428086 2022-07-26

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

19 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT02711969 2022-07-22

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

6 enrolled

Stomach Neoplasms

NCT02945852 2022-07-19

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Thoracic

Small Cell Lung Carcinoma

NCT03042611 2022-07-08

ANGEL

460 enrolled 16 charts

Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

98 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

66 enrolled

Advanced Triple-Negative Breast Cancer

NCT03104283 2022-03-15

Apatinib for the Elderly Advanced Gastric Cancer

48 enrolled

Stomach Neoplasms

NCT04188847 2022-03-15

First-line Chemotherapy for Recurrent Cervical Cancer

37 enrolled

Uterine Cervical Neoplasms

NCT04690231 2022-03-15

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Phase NA Completed

79 enrolled

Sarcoma

Osteosarcoma, Drug-Related Side Effects and Adverse Reactions

NCT02764268 2022-03-11

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Phase NA Completed

60 enrolled

Stomach Neoplasms

NCT03243838 2022-02-02

LANCET

31 enrolled

Triple Negative Breast Neoplasms

NCT02731352 2022-01-20

Study of Apatinib in Patients With Differentiated Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT04047017 2021-07-30

GTN

20 enrolled

Recurrence, Gestational Trophoblastic Disease

NCT04642664 2021-06-03

ACABC

22 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT02645864 2021-03-18

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

12 enrolled

Esophageal Squamous Cell Carcinoma

NCT02878057 2021-01-27

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

30 enrolled 12 charts

Breast Neoplasms

NCT03274011 2021-01-26

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms

NCT04260113 2021-01-05

AIAC

Phase NA Completed

Sarcoma

Chondrosarcoma, Drug-Related Side Effects and Adverse Reactions

NCT03251443 2020-12-02

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

34 enrolled